Company research
MAXCYTE, INC.
CIK 1287098Updated Sep 24, 2026
SecurityMXCT · NASDAQ · equity
Historical securities (1)
MAXC · OTC · equity · closed Mar 10, 2021Name history
MAXCYTE INC · through Sep 18, 2008
MXCT price & chart
Loading TradingView…
NASDAQ:MXCT on TradingView ↗About the company
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.
In the news
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 202,507,000Source | 239,470,000Source | 268,274,000Source | 286,653,400Source |
| Property, Plant and Equipment, NetUSD | 17,531,000Source | 19,707,000Source | 23,513,000Source | 23,724,700Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 650,000Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,065,000Source | 27,884,000Source | 46,506,000Source | 11,064,700Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,503,000Source | 4,682,000Source | 5,778,000Source | 11,654,600Source |
| Inventory, NetUSD | 7,547,000Source | 8,914,000Source | 12,229,000Source | 8,580,800Source |
| Assets, CurrentUSD | 118,369,000Source | 171,684,000Source | 190,194,000Source | 252,266,200Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,275,000Source | 3,606,000Source | 3,899,000Source | 2,778,800Source |
| Operating Lease, Right-of-Use AssetUSD | 10,920,000Source | 10,766,000Source | 11,241,000Source | 9,853,500Source |
| Other Assets, NoncurrentUSD | 2,467,000Source | 1,532,000Source | 388,000Source | 809,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 31,017,000Source | 33,219,000Source | 36,107,000Source | 32,686,200Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,068,000Source | 1,057,000Source | 1,040,000Source | 1,024,000Source |
| Additional Paid in CapitalUSD | 431,905,000Source | 422,047,000Source | 406,925,000Source | 390,818,500Source |
| Retained Earnings (Accumulated Deficit)USD | -261,483,000Source | -216,853,000Source | -175,798,000Source | -137,875,300Source |
| Stockholders' Equity Attributable to ParentUSD | 171,490,000Source | 206,251,000Source | 232,167,000Source | 253,967,200Source |
| Liabilities and EquityUSD | 202,507,000Source | 239,470,000Source | 268,274,000Source | 286,653,400Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 14,267,000Source | 15,775,000Source | 17,855,000Source | 15,426,500Source |
| Operating Lease, Liability, CurrentUSD | 1,456,000Source | 864,000Source | 774,000Source | 156,800Source |
| Accounts Payable, CurrentUSD | 1,401,000Source | 1,358,000Source | 743,000Source | 531,800Source |
| Operating Lease, Liability, NoncurrentUSD | 16,487,000Source | 17,170,000Source | 17,969,000Source | 15,938,100Source |
| Other Liabilities, NoncurrentUSD | 263,000Source | 274,000Source | 283,000Source | 1,321,600Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 3,598,000Source | 5,251,000Source | 5,069,000Source | 6,712,600Source |
| Short-term InvestmentsUSD | 82,979,000Source | 126,598,000Source | 121,782,000Source | 216,274,900Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -44,630,000Source | -41,055,000Source | -37,923,000Source | -23,570,800Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,340,000Source | 4,315,000Source | 4,171,000Source | 2,697,900Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,213,000Source | 13,083,000Source | 13,979,000Source | 11,752,400Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,148,000Source | -1,226,000Source | -5,226,000Source | 4,777,600Source |
| Increase (Decrease) in InventoriesUSD | -575,000Source | -1,362,000Source | 4,534,000Source | 3,493,300Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -34,410,000Source | -27,610,000Source | -21,686,000Source | -14,782,900Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 1,773,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 25,935,000Source | 6,932,000Source | 54,984,000Source | -24,823,300Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,768,000Source | 1,651,000Source | 3,700,000Source | 18,477,200Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 656,000Source | 2,056,000Source | 2,143,000Source | 2,888,500Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -7,819,000Source | -18,622,000Source | 35,441,000Source | -36,717,700Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 20,065,000Source | 27,884,000Source | 46,506,000Source | 11,064,700Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 9,213,000Source | 13,083,000Source | 13,979,000Source | 11,752,400Source |
| Amortization of Intangible AssetsUSD | 53,000Source | — | — | — |
| Deferred Other Tax Expense (Benefit)USD | 11,812,000Source | 9,228,000Source | 12,294,000Source | 3,240,500Source |
| DepreciationUSD | 4,287,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -70,000Source | -140,000Source | -84Source | -79,100Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -287,000Source | -861,000Source | -30,000Source | -139,500Source |
| General and Administrative ExpenseUSD | 28,116,000Source | 29,693,000Source | 30,068,000Source | 25,828,700Source |
| Goodwill, Impairment LossUSD | 3,554,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | — | — |
| Inventory Write-downUSD | 676,000Source | 1,771,000Source | 697,000Source | — |
| Investment Income, InterestUSD | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,916,600Source |
| Net Income (Loss) Attributable to ParentUSD | -44,630,000Source | -41,055,000Source | -37,923,000Source | -23,570,800Source |
| Operating ExpensesUSD | 78,701,000Source | 82,724,000Source | 84,845,000Source | 66,523,600Source |
| Operating Lease, Lease IncomeUSD | 12,069,000Source | 16,412,000Source | 21,791,000Source | 15,512,600Source |
| Other Nonoperating Income (Expense)USD | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,789,700Source |
| Payments to Acquire InvestmentsUSD | 126,286,000Source | 150,857,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 432,000Source | 1,597,000Source | 1,874,000Source | 2,888,500Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 20,957,000Source | 22,215,000Source | — | 28,748,900Source |
| Cost of RevenueUSD | 6,222,000Source | 7,100,000Source | 4,742,000Source | 5,098,400Source |
| Operating Income (Loss)USD | -51,897,000Source | -51,197,000Source | -48,299,000Source | -27,360,500Source |
| Other Nonoperating Income (Expense)USD | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,789,700Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -44,630,000Source | -41,055,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -44,630,000Source | -41,055,000Source | -37,923,000Source | -23,570,800Source |
| Earnings Per Share, BasicUSD per share | -0.42Source | -0.39Source | -0.37Source | -0.23Source |
| Earnings Per Share, DilutedUSD per share | -0.42Source | -0.39Source | -0.37Source | -0.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 106,427,854Source | 104,849,222Source | 103,268,502Source | 101,702,664Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 106,427,854Source | 104,849,222Source | 103,268,502Source | 101,702,664Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 53,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,226,000Source | 4,143,000Source | 3,985,000Source | 2,527,600Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -70,000Source | -140,000Source | -84Source | -79,100Source |
| General and Administrative ExpenseUSD | 28,116,000Source | 29,693,000Source | 30,068,000Source | 25,828,700Source |
| Goodwill, Impairment LossUSD | 3,554,000Source | — | — | — |
| Gross ProfitUSD | 26,804,000Source | 31,527,000Source | 36,546,000Source | 39,163,100Source |
| Investment Income, InterestUSD | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,916,600Source |
| Operating ExpensesUSD | 78,701,000Source | 82,724,000Source | 84,845,000Source | 66,523,600Source |
| Operating Lease, Lease IncomeUSD | 12,069,000Source | 16,412,000Source | 21,791,000Source | 15,512,600Source |
| Research and Development ExpenseUSD | 20,823,000Source | 22,227,000Source | 23,817,000Source | 19,514,400Source |
| Selling and Marketing ExpenseUSD | 18,924,000Source | 26,661,000Source | 26,975,000Source | 18,652,900Source |
Filing attachments
mxct-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 mxct-20260812xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board Following end of quarter, announced s…
Read attachment ↗mxct-20260812xex99d2.htm · 8-K · 2026-08-12
EX-99.2 3 mxct-20260812xex99d2.htm EX-99.2 Exhibit 99.2 are trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT August 2026 © 2026 MaxCyte, Inc. All Rights Reserved ───────────────────────────────────────────────── Forward Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forwa…
Read attachment ↗mxct-20260512xex99d1.htm · 8-K · 2026-05-12
EX-99.1 2 mxct-20260512xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte’s Board authorized a $10 million share repur…
Read attachment ↗mxct-20260512xex99d2.htm · 8-K · 2026-05-12
EX-99.2 3 mxct-20260512xex99d2.htm EX-99.2 Exhibit 99.2 are trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT May 2026 © 2026 MaxCyte, Inc. All Rights Reserved ───────────────────────────────────────────────── Forward Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forward-…
Read attachment ↗mxct-20260323xex99d1.htm · 8-K · 2026-03-27
EX-99.1 2 mxct-20260323xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) - MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja su…
Read attachment ↗mxct-20260324xex99d1.htm · 8-K · 2026-03-24
EX-99.1 2 mxct-20260324xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at …
Read attachment ↗